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Objectives. Carotid bodies (CBs) play an important role in regulating sympathetic nervous system activity. (us, they are
likely to be enlarged in patients with certain cardiovascular and respiratory diseases. (e aim of this case-control study was
to verify this hypothesis using computed tomography angiography (CTA). Methods. We retrospectively analysed 141 CTAs
including 16 controls, 96 patients with only hypertension (HT), 12 with HTand previous acute myocardial infarction (AMI),
9 with HT and heart failure (HF), and 8 with HT and chronic obstructive pulmonary disease (COPD). We assessed the data
using analysis of variance, with p< 0.05 indicating significance. Results. CB average areas in the controls were 2.31 mm2
(right side (RS)) vs. 2.34mm2 (left side (LS)). CB size was significantly enlarged in patients with HT: 3.07mm2 (RS)
(p � 0.019) vs. 2.91 mm2 (LS) (p � 0.002). If AMI (RS: 3.5 mm2; LS: 3.44mm2) or HF (RS: 4.01 mm2; LS: 4.55mm2) was
associated with HT, the CB size was even more enlarged. COPD did not affect CB size (RS: 2.40 mm2; LS: 2.29mm2).
Conclusions. Our data showed that certain diseases with increased activity of the sympathetic nervous system were as-
sociated with significantly enlarged CBs.
1. Introduction
Carotid bodies (CBs) are small, paired organs that contain
peripheral chemoreceptors and chromaffin cells. Richly
supplied by blood vessels, CBs are located above the bi-
furcation of the common carotid artery. (e amount of
blood that flows through CBs is 20 times their weight per
minute. (eir main role is to sense the pressure of certain
gases in the blood that passes through them, especially the
partial pressure of O2 and CO2, as well as to monitor the pH
level [1–4].
According to the literature, mitochondria in the glomus
cells of CBs are sensitive to hypoxia. (erefore, if the arterial
partial O2 pressure decreases, the central nervous system is
informed, resulting in the ventilation being stimulated. In
addition to chemoreceptors, baroreceptors and thermore-
ceptors are also present, and some studies suggest that they
play a role in glucose homeostasis as well. CBs are essential
to regulating respiration and the blood circulation [5–8].
With their chromaffin cells, CBs take part in relevant pro-
cesses of the sympathetic nervous system. By producing
adrenaline and noradrenaline, they compensate the hypo-
xaemia-induced direct vasodilatation effect, promoting
better adaptation [9, 10].
(e hyperactivity of the chromaffin cells and their in-
creased mass have been observed in patients with certain
cardiovascular and respiratory diseases. Furthermore, the
pathological processes of the liver and some metabolic or
haematological states have an influence on the size of CBs’
cells. Several articles have described the enlargement of CBs
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but did not compare the extent of the enlargement in the
different diseases [11–21].
Previous studies with small groups of patients have
shown that we can identify CBs reliably by computed to-
mography angiography (CTA) and can determine their
exact size. We can identify CBs by searching for an avidly
enhancing structure in its characteristic location, at the
inferomedial aspect of the carotid bifurcation [22, 23].
(e aim of this case-control study was to verify the en-
largement of CBs with the help of CTA in a large number of
patients with the following conditions: hypertension (HT);
heart failure (HF) andHT; acute myocardial infarction (AMI)
and HT; and chronic obstructive pulmonary disease (COPD)
and HT. (e second aim of the study was to determine the
extent of the enlargement of CBs in the presence of the
abovementioned conditions. Our purpose was to compare the
measured data in order to better understand the operation of
CBs and draw conclusions about their functions.
2. Materials and Methods
2.1. Study Group. (e first phase of our study was to collect
the records of neck carotid CTAs performed in the centre of
Affidea Hungary Ltd., Szeged, during a one-year period. In
total, 512 examinations were performed. (en, the condi-
tions of the patients were investigated precisely with the help
of the hospital informatics system Medsolution (Interna-
tional System House (ISH) Ltd., Budapest, Hungary). (e
International Statistical Classification of Diseases and Re-
lated Health Problems coding system provided significant
help in this research. In all, 150 patients were found with
sufficient information relevant to the study. Some diseases
influence the size of CBs, including lesions of the liver (e.g.,
liver cirrhosis and hepatitis) and haematological or meta-
bolic diseases (e.g., lactate acidosis and haemoglobinopathy).
As only two patients suffered from liver cirrhosis, it was not
enough for statistical analysis, so we excluded them from the
study. Exclusionary haematological diseases or lactate aci-
dosis could not be verified in any of the patients. In seven
cases, we found more than two of the examined illnesses.
Finally, 141 patients met the previously determined criteria
and were classified according their conditions.(ere were 16
controls. HT alone was identified in 96 patients, HT asso-
ciated with AMI in 12 patients, HF and HT in 9 patients, and
COPD associated with HT in 8 patients.
All patients who suffered from HT had essential HT, and
it was proven further by the criteria of blood pressure
measurements. In all questionable cases, the patient under-
went 24-hour ambulatory blood pressure monitoring
(ABPM). In case the patient had an episode with typical ECG
signs and the typical blood test, with elevated troponin level
and creatine kinase level, AMI was proven in the anamnesis.
In case of HF, the diagnosis was proven by echocardiography
and the increased level of N-terminal pro-B-type natriuretic
peptide (NT-proBNP) in the blood test. COPD was identified
if spirometry proved the diagnosis by the decrease of forced
expiratory volume during the first second (FEV1) and the
decrease of the Tiffeneau-Pinelli index below 70%. Detailed
information about the study groups is given in Table 1.
2.2. Measurement and Evaluation. (e examinations were
performed by using a 64-slice GE LightSpeed VCT XTe CT
Scanner (General Electric, Fairfield, Connecticut, USA). (e
slices were obtained in the helical mode with 1.25mm slice
thickness. Patients were scanned from the aortic arch to the
frontal sinus. (e contrast agent (Omnipaque 350-General
Electric, Fairfield, Connecticut, USA) was injected intra-
venously via an 18-gauge peripheral venous catheter. We
used an antecubital vein if possible. When it was not feasible,
the contrast material was injected into the dorsal venous
network of the hand, with 50ml of it used for each exam-
ination. We first administered 15ml of contrast material at a
rate of 2.5ml/s and then 35ml at a rate of 3.0ml/s, followed
by a 25ml saline flush.
We managed the process with the SmartPrep technique.
We began the examination when the contrast agent
appeared in the region of interest which was in the aortic
arch. (e scans were uploaded to the Picture Archiving and
Communication System database of GE. One of the authors,
who was unaware of the clinical conditions of the patients,
executed the identification and measurement of CBs twice at
different times.
An axial scan was chosen for evaluation in each case
because CBs could be best identified on axial scans. We used
magnification if necessary.Wemeasured the anteroposterior
and the latero-lateral diameters of CBs on both sides on two
occasions. (e two measured areas were then averaged and
used as final data. Figure 1 shows the identification pro-
cesses. Figures 2 and 3 show examples from the examined
groups.
2.3. Statistical Analysis. (e analysis and evaluation of data
were performed with SigmaPlot software package (version
13; SYSTAT Software Company Inc., San Jose, CA, USA).
(e Shapiro−Wilk test was used to test data for normality.
(e Kruskal−Wallis one-way analysis of variance on ranks
test was executed to compare the results of all of the groups
with each other, with p< 0.05 indicating significance.
Dunn’s multiple comparison procedure was applied to
compare the groups. We also compared the measured data
of the two measurement series (intraobserver variability)
with the help of the Wilcoxon test.
3. Results
Successful identification of CBs was the primary criteria in
the evaluation of the measured data. (e identification was
considered successful only if CBs were found on two sep-
arate occasions. (e measured data were recorded and
evaluated rigorously on both the right side (RS) and the left
side (LS). On the RS, CBs were precisely detected in 129 of
the 141 patients, with a success rate of 91%. Identification
was even more successful on the LS, where they were clearly
measured in 134 patients, with a 95% success rate.
We examined the two measurement series and com-
pared them with each other to determine intraobserver
variability. (e average size± standard deviation of the CB
on the RS was 3.05± 0.97mm2 for the first measurement
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series and 3.04± 0.89mm2 for the second one. On the LS, the
average CB size was 2.94± 0.88mm2 for the first measure-
ment series and 2.95± 0.87mm2 for the second series. No
significant intraobserver variability was found for the cross-
sectional areas (p � 0.54 for the RS and p � 0.42 for the LS).
In the control group, the average size of the CB was
2.31± 0.82mm2 on the RS and 2.34± 0.66mm2 on the LS.
(ere was no significant difference between the two sides.
(e CB was larger in the HT-only patients (3.07± 0.81mm2
on the RS and 2.91± 0.74mm2 on the LS) than in the control
group. On the RS, there was a significant difference in its size
between the HT-only patients and the control group
(p � 0.019). On the LS, the difference was clear, but it was
not quite at the level of significance (p � 0.079). In patients
with AMI and HT, the average size of the CB was
3.5± 0.74mm2 on the RS and 3.44± 0.72mm2 on the LS.(e
measured data showed exactly the same tendency as in our
previous assumptions: the CB was larger in patients with a
prior heart attack and HT than in the HT-only patients or
the controls. In the latter case, the difference was significant
on both sides (p � 0.002 in both cases). Compared with
patients with HT, the difference is detectable but not
Table 1: Data for all patient groups.
Patient groups Control HT AMI+HT HF+HT COPD+HT Altogether
Number of patients 16 96 12 9 8 141
Female 7 47 3 5 4 66
Male 9 49 9 4 4 75
Average age (Min–Max in years) 48.63 (21–78) 65.79 (29–88) 63.58 (44–85) 65.78 (29–88) 65.38 (58–72) 61.83 (21–88)
HT, hypertension only; AMI +HT, previous acute myocardial infarction and hypertension; HF +HT, heart failure and hypertension; COPD+HT, chronic
obstructive pulmonary disease and hypertension.
Figure 1: Images from a 53-year-old man in the control group (right: caudal image in which the small, avidly enhancing left carotid body
(CB) (black arrow) is seen between the external carotid artery (smaller one on the ventral side) and the internal carotid artery (larger one on
the dorsal side); left: a somewhat more cranial image in which the narrow branch of the external carotid artery (white arrows) is easily
differentiated from the carotid body).
Figure 2: CTA shows moderately enlarged carotid bodies (arrow) on both sides in a 54-year-old woman who suffers from high blood
pressure.
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significant (p � 0.583 on the RS and p � 0.180 on the LS).
(us, patients with HF and HT had the largest CBs, with an
average dimension of 4.01± 1.39mm2 on the RS and
4.55± 1.24mm2 on the LS. Compared with the control
group, significance was obvious on both sides (p � 0.003 on
the RS and p< 0.001 on the LS).
(e average size of the CB in patients with COPD and
HTwas 2.40± 0.54mm2 on the RS. It can be seen that the CB
is smaller in these patients than in those who had HTalone.
(e size is almost the same as in the control group. No
significant difference could be observed among the three
groups. Statistically, the CB in patients who had COPD and
HT was significantly smaller than that in patients with HT
and HF and in those with HTand AMI (p � 0.026 in the first
case and p � 0.033 in the second). Measurements on the LS
showed the same results: the size of the CB was
2.29± 0.27mm2. We found a significant difference with the
HT and HF group (p< 0.001) and with the HT and AMI
group (p � 0.005). We also compared the COPD and HT
group with the control patients and the HT-only group on
the LS. We could not identify a significant difference in
either case.
(e right and left sides were compared with each other in
every examined group, with no significant differences found.
(e number of identified CBs, the success rate of identifi-
cation, and the average size of CBs for the right side are
shown in Table 2, and those for the left side are shown in
Table 3. Figures 4 and 5 show the results and the significant
pairs. (e significant pairs and p values for every case are
shown in Table 4.
4. Discussion
It is well known that CBs play an important role in reg-
ulating the respiratory and blood circulation systems. (ey
are the most important chemosensors, baroreceptors, and
thermoreceptors in the human body besides the brain.
(ese sensors instigate the flow of information to the
central nervous system about possible hypoxia. (eir
chromaffin cells participate in the activity of the sympa-
thetic nervous system as well. As it is known, these cells are
mostly located in the medulla of the adrenal gland. (ey
produce noradrenaline and adrenaline, thereby playing a
role in stimulating the sympathetic nervous system. It is
important to compensate for the hypoxaemia-induced
direct vasodilatation effect, thereby helping improve ad-
aptation [3–10].
CBs enlarge significantly in the presence of cardiovas-
cular diseases such as HT or HF. Moreover, it seems that
respiratory diseases such as COPD and pathological pro-
cesses of the liver as well as some metabolic or haemato-
logical states also influence the size and histologic structure
of CBs. In these cases, the sympathetic nervous systemmight
be overactivated, so the number of the chromaffin cells in
this system could be increased. (e role of CBs in the
formation, progression, and maintenance of these diseases is
still not fully clarified. (e main problem is that some of the
available data about CBs are derived from postmortem
examinations, animal experiments, and studies with small
groups of patients [7, 9, 12–14].
In patients with HT or HF or following AMI, the
sympathetic tone could be intensified. In this study, we
intended to evaluate the morphological signs related to this
role of the CB based on alteration of its size. Hence, the
carotid CTA examinations of 141 patients were reanalysed
retrospectively. It was clearly proved that CBs could be
reliably identified using this technique, with a success rate of
>90%. Advanced calcification around the bifurcation or on a
previously built-in metal stent makes measurement more
difficult, as either situation deforms the normal anatomic
conditions. As can be seen in Figure 3, there were some cases
in which the size of the CB could be clearly measured despite
the complicating conditions. Jie et al. [12] examined CBs by
ultrasound. Even though they had studied a larger group, we
could achieve a higher success rate of identification by our
CTA study.
Our results confirmed that CBs are significantly enlarged
in patients with HT. Previously, Habeck et al. [13] and Honig
et al. [14] verified the enlargement of CBs in rats with high
blood pressure. Presumably, because of the permanently
increased activity of the sympathetic nervous system, the
volume and number of chromaffin cells increase, thereby
increasing the size of the CB. (e significant enlargement
proven by the measurements verified our assumptions and
confirmed the results of previous studies. Sreejit et al. [23]
proved that the volume of CBs also grows in patients with
both HT and HF. Based on previous pathologic and path-
ophysiologic data, it is obvious that the simultaneous
presence of the two diseases would further increase the
sympathetic activity. Our CTA results verified this tendency
of increase in vital situations. We measured significantly
larger volumes on both sides in patients with both HT and
HF versus the control group and the HT-only group. We
also found that if the patients had not only HT but also a
previous AMI, CBs had enlarged, although its size did not
reach that in the HTand HF group. Perhaps the durations of
the two diseases were responsible for the difference in the
amount of enlargement.
Figure 3: CTA axial slice from an 84-year-old man who had
experienced a previous AMI and suffers from HT. (e patient also
had had a carotid stent implanted, but the enlarged CB (arrow) is
still easily identified.
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Based on previous studies, we assumed that the diameter
of CBs enlarges in patients with COPD. Our measured data,
however, did not corroborate that tendency. (e recorded
sizes on both sides were nearly the same as those in the
control group with no significant difference. In a recent
article, Vinhaes et al. [24] proved histologically that the
construction of cells and their proportions change not only
in COPD patients but also in those with acute respiratory
distress syndrome. We thus assume that the increase in size
is not the main determining change in COPD. Histologic
remodelling is probably much more important in these
diseases. Another reason we may not find larger areas is that
COPD is an umbrella designation under which various
illnesses reside. (ese different types of disease could affect
CBs in different ways and to different degrees. Further
analysis of the relations could be useful.
(ere are some limitations of our study, which we intend
to solve in the future. First, it was not possible to measure
catecholamine production by CBs directly, so we judged this
function according to CB size. Second, although our study is
based on a large group of patients, some of the subgroups
were small. (us, we have the data about medication of
patients and the stage or grade of examined diseases; these
could not submit accurate statistical analysis. It would be
interesting to examine the nontreated or the not appro-
priately treated cases in separate groups. (is evaluation
could provide evidence to prove that the size of CBs correlate

























Figure 4: Our results and significant pairs ( ∗p< 0.05 and
∗∗p< 0.01) for the right-side carotid bodies with the standard
deviations. HT, hypertension; AMI, acute myocardial infarction;
HF, heart failure; COPD, chronic obstructive pulmonary disease.

























Figure 5: Significant differences ( ∗p< 0.05, ∗∗p< 0.01, and
∗∗∗p< 0.001) and the measured cross-sectional sizes of the left-side
carotid bodies.
Table 2: Success rate of identification and comparison of cross-sectional areas of the right CB.
Right side Control HT AMI+HT HF+HT COPD+HT
Identified CBs 15 89 11 7 7
Success rate of identification (%) 93.75 92.7 91.67 77.78 87.5
Mean size of the CB (mm2) 2.31 3.07 3.56 4.01 2.40
Standard deviation (±) 0.82 0.81 0.74 1.39 0.54
Table 3: Success rate of identification and comparison of cross-sectional areas of the left CB.
Left side Control HT AMI+HT HF+HT COPD+HT
Identified CBs 16 91 12 7 8
Success rate of identification (%) 100 92.71 100 77.78 100
Mean size of the CB (mm2) 2.34 2.91 3.44 4.55 2.29
Standard deviation (±) 0.66 0.74 0.72 1.24 0.27
Table 4: Significant pairs on the right and left sides using the p
value.
Right side p Left side p
Control HT 0.019 Control AMI+HT 0.002
Control AMI+HT 0.002 Control HF +HT <0.001
Control HF+HT 0.003 HT HF+HT 0.005
COPD+HT AMI+HT 0.033 COPD+HT AMI+HT 0.005
COPD+HT HF+HT 0.026 COPD+HT HF+HT <0.001
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with the medical treatment and with the severity of the
disease. It could be the subject of our following study.
(e aims for the future are to widen the group of examined
patients and to execute prospective measurements. (ese ad-
ditions would provide more accurate information from the
patients, and the abovementioned obstacles could be eliminated.
Further improvement could be achieved if the resolution was
enhanced and if the measurements were done on, for example,
MRI scans as well or were compared with them [25–27].
5. Conclusion
We proved, using CTA, that CBs are indeed enlarged in
patients with diseases that cause the sympathetic nervous
system’s operation to be intensified. Based on our mea-
surements in patients with HT, the diameter of CBs is sig-
nificantly larger than that of CBs in the average, healthy
individuals. Its size further enlarges in patients who in ad-
dition to HT also have HF or AMI in the anamnesis. Taking
our measurements into consideration allows the possibility of
drawing conclusions about the physiologic and general state
of the patient after analysing his or her anatomic structures on
CTA.(is protocol could provide us and clinicians additional
information about the patient. In the future, it could be in-
teresting to increase the number of patients and to analyse
precisely the treatment used. It would allow the possibility of
determining the efficacy of treatment of these diseases.
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phy; and (3) the carotid body is enlarged in certain diseases
with increased sympathetic activity.
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